Austar Lifesciences Ltd
06118
Company Profile
Business description
Austar Lifesciences Ltd is engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipments and consumables in the People’s Republic of China. The company’s segments include Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC). Geographically, it derives the majority of its revenue from Mainland China.
Contact
No.1018 Changning Road
Rooms 2010-2013, 20th Floor
Changning District
Shanghai
CHNT: +86 4008121586
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
1,445
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.60 | 41.00 | 0.45% |
| CAC 40 | 7,720.25 | 22.75 | -0.29% |
| DAX 40 | 24,065.85 | 97.01 | -0.40% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,116.49 | 20.76 | 0.23% |
| HKSE | 24,906.81 | 47.99 | 0.19% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,911.86 | 67.23 | 0.52% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,844.80 | 37.70 | 0.43% |
| SSE Composite Index | 3,647.55 | 12.42 | 0.34% |